Piper Jaffray analyst Danielle Brill kept her Overweight rating and $75 price target on Acceleron, saying the company's "under-the-radar" sotatercept, or sota, "has the potential to become the first disease modifying agent" in pulmonary arterial hypertension. The analyst states that the drug is the only treatment with demonstrated ability to reduce the vascular muscularization of the disease and points to the company's starting to enroll patients in a Phase 2 Pulsar trial. Brill anticipates top-line data from the trial to be available in the first half of 2020.